U.S. Approval, Sales Milestones Could Double PneumRx Price For BTG
This article was originally published in The Gray Sheet
Contingency payments based on regulatory and sales milestones for lead emphysema product RePneu could double the price BTG pays for U.S. biotech PneumRx, the latest addition to the United Kingdom company’s interventional medicines business.
You may also be interested in...
Minimally invasive emphysema devices have seen their ups and downs over the years, but despite technological and regulatory challenges, VCs continue to fund these devices, with investments driven by the market opportunity, huge unmet clinical need, and promising technologies.
A regulatory framework that encourages physicians to conduct experimental cell and gene therapies have propelled China to become a major developer of such promising cancer-treating tools, but insiders say three are a plethora issues at stake.